CALDARA, ALESSIA
CALDARA, ALESSIA
Dipartimento di Scienze Giuridiche Cesare Beccaria
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
2023 A. Fabi, L. Carbognin, A. Botticelli, I. Paris, P. Fuso, M.C. Savastano, N. La Verde, C. Strina, R. Pedersini, S. Guarino, G. Curigliano, C. Criscitiello, M. Raffaele, A. Beano, A. Franco, M.R. Valerio, F. Verderame, A. Fontana, E.R. Haspinger, A. Caldara, A. Di Leone, G. Tortora, D. Giannarelli, G. Scambia
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer
2023 A. Fabi, L. Carbognin, A. Botticelli, I. Paris, P. Fuso, M.C. Savastano, N. La Verde, C. Strina, R. Pedersini, S. Guarino, G. Curigliano, C. Criscitiello, M. Raffaele, A. Beano, A. Franco, M.R. Valerio, F. Verderame, A. Fontana, E.R. Haspinger, A. Caldara, A. Di Leone, G. Tortora, D. Giannarelli, G. Scambia
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
2022 S. Cavalieri, M. Serena Serafini, A. Carenzo, S. Canevari, D. Lenoci, F. Pistore, R. Miceli, S. Vecchio, D. Ferrari, C. Moro, A. Sponghini, A. Caldara, M. Cossu Rocca, S. Secondino, G. Moretti, N. Denaro, F. Caponigro, E. Vaccher, G. Rinaldi, F. Ferraù, P. Bossi, L.F.L. Licitra, L. de cecco
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
2017 P. Bossi, R. Miceli, L..D. Locati, D. Ferrari, S. Vecchio, G. Moretti, N. Denaro, F. Caponigro, M. Airoldi, C. Moro, E. Vaccher, A. Sponghini, A. Caldara, S.G. Rinaldi, F. Ferrau, F. Nolè, S. Lo Vullo, F. Tettamanzi, L. Hollander, L.F.L. Licitra